Cargando…
Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation
Vascular calcification (VC) is associated with increased cardiovascular risks in patients with chronic kidney disease (CKD). Sodium-glucose cotransporter 2 inhibitors, such as empagliflozin, can improve cardiovascular and renal outcomes. We assessed the expression of Runt-related transcription facto...
Autores principales: | Lu, Chia-Wen, Lee, Chung-Jen, Hsieh, Yi-Jen, Hsu, Bang-Gee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298656/ https://www.ncbi.nlm.nih.gov/pubmed/37373164 http://dx.doi.org/10.3390/ijms241210016 |
Ejemplares similares
-
Vascular calcification of chronic kidney disease: A brief review
por: Hsu, Bang-Gee, et al.
Publicado: (2020) -
Linagliptin Protects against Endotoxin-Induced Acute Kidney Injury in Rats by Decreasing Inflammatory Cytokines and Reactive Oxygen Species
por: Wu, Tsung-Jui, et al.
Publicado: (2021) -
Review of the organisation and working methods of the NFR
por: Brennan, Max, et al.
Publicado: (1998) -
Vitamin K and vascular calcification in chronic kidney disease: An update of current evidence
por: Lin, Yu-Li, et al.
Publicado: (2022) -
Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus
por: Chi, Po-Jui, et al.
Publicado: (2022)